Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


AM-Pharma announces 2.5 million EURO financing
AM-Pharma financing kick-starts Series C financing effort


Bunnik, The Netherlands, 6 August 2007: AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the signing of a 2.5 million Euro financing agreement with its two main investors, Forbion Capital Partners and Inventages Venture Capital.

The investment is a prelude to a Series C financing round, for which AM-Pharma is now in discussion with potential investors from both Europe and the US. AM-Pharma’s main investors aim to participate further in this Series C financing, which will close before the end of this year. Cash raised in the upcoming round will allow the company to generate Phase II efficacy and safety data for two products; recombinant human Alkaline Phosphatase and Anti-Microbial Peptide hLF1-11, in four therapeutic indications; Acute Renal Failure; Ulcerative Colitis; hospital acquired bacterial infections and systemic Candida infection, during the next three years. In this period the value of AM-Pharma is expected to grow significantly.

AM-Pharma recently announced positive results in two Phase IIa studies with Alkaline Phosphatase in Acute Renal Failure and Ulcerative Colitis, whilst Anti-Microbial peptide hLF1-11 showed to be safe in a first trial in bone marrow transplant patients.

Bart Wuurman, CEO commented: “It’s great that our two main investors continue to give us strong support in moving our clinical programmes forward. Considering our recent positive clinical results and the strength of our product portfolio, the Series C round we have started now may well be the last round before exit.”

Gunnar Weikert of Inventages added: “The clinical progress and data shown so far by the company are encouraging. This is one of the few companies that have four products in Phase II development and we look forward to further participation in the Series C round.”

Bart Bergstein of Forbion Capital Partners pointed out: “AM-Pharma has reached the typical period where value inclination points will be reached. Given the strong pipeline, the expectation of a liquidity event via an IPO or trade sale in the upcoming period is more realistic than ever.”

-ENDS-

Notes to editors:

About AM-Pharma www.am-pharma.com
AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of novel compounds in the field of severe infectious diseases and inflammatory diseases. All its products are based on endogenous molecules which have been optimised to combat disease.

AM-Pharma is conducting Phase II clinical trials for two products; Alkaline Phosphatase for acute renal failure and ulcerative colitis; and Anti-microbial Peptide hLF1-11 for the prevention of infections in hemopoietic stem cell transplant patients. hLF1-11 is also in pre-clinical development for treatment of drug resistant hospital acquired bacterial infections and for treatment of systemic Candida infections.

AM-Pharma is based in Bunnik, The Netherlands with a staff of 20. The company is financed by, amongst others, Forbion Capital Partners, Inventages Venture Capital and Theratase plc. Once product safety and efficacy have been established, AM-Pharma will look for world-wide development and marketing partners for its products.

About Inventages www.inventages.com

Inventages Venture Capital is one of the world´s largest venture/private equity funds specializing in life sciences, with more than $1.5 billion under management. Inventages’ investment focus includes pharmaceuticals, nutraceuticals, medical food, nutrition, cosmeceuticals, innovative food, as well as, consumer relation management, processes and novel packaging technologies. Inventages operates from three offices around the globe in Auckland, Geneva and Nassau.

About Forbion www.forbion.com

Forbion Capital Partners invests in EU and US Life Sciences companies with a focus on drug development and medical technologies. The Forbion team


Publisher Contact Information:

AM-Pharma BV
+31 (0)30 2289222
b.wuurman@am-pharma.com

Company profile of AM-Pharma BV
Past press releases of AM-Pharma BV.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.